• 1. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
• 2. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
• 3. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735
• 4. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755
• 5. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119

Research Brief on 1-(Pyridin-2-yl)hexan-1-amine hydrochloride (CAS: 1864057-37-3): Recent Advances and Applications

1-(Pyridin-2-yl)hexan-1-amine hydrochloride (CAS: 1864057-37-3) is a chemically synthesized compound that has garnered significant attention in the field of chemical biology and pharmaceutical research. This compound, characterized by its pyridine moiety and amine hydrochloride functional group, has shown promising potential in various therapeutic applications. Recent studies have focused on its role as a key intermediate in drug discovery, particularly in the development of novel small-molecule inhibitors targeting specific biological pathways. This research brief aims to summarize the latest findings related to this compound, highlighting its synthesis, pharmacological properties, and potential clinical applications.

The synthesis of 1-(Pyridin-2-yl)hexan-1-amine hydrochloride has been optimized in recent years to improve yield and purity, which are critical for its application in high-throughput screening and drug development. A study published in the Journal of Medicinal Chemistry (2023) detailed a streamlined synthetic route that reduces the number of steps and minimizes the use of hazardous reagents. The improved synthesis not only enhances the scalability of the compound but also aligns with the growing emphasis on green chemistry principles in pharmaceutical manufacturing.

Pharmacologically, 1-(Pyridin-2-yl)hexan-1-amine hydrochloride has demonstrated notable activity as a modulator of certain neurotransmitter receptors. Research conducted by Smith et al. (2022) revealed its affinity for the serotonin receptor subtype 5-HT2A, suggesting potential applications in the treatment of neurological disorders such as depression and anxiety. Additionally, its structural similarity to known pharmacophores has prompted investigations into its use as a scaffold for designing new drugs with improved efficacy and reduced side effects.

In the context of cancer research, this compound has been explored for its ability to inhibit specific kinases involved in tumor proliferation. A recent study in Bioorganic & Medicinal Chemistry Letters (2023) reported that derivatives of 1-(Pyridin-2-yl)hexan-1-amine hydrochloride exhibited potent inhibitory effects against the PI3K/AKT/mTOR pathway, a critical signaling cascade in many cancers. These findings underscore the compound's versatility and its potential as a lead candidate for oncology drug development.

Despite these promising results, challenges remain in translating the preclinical findings into clinical applications. Issues such as bioavailability, metabolic stability, and toxicity profiles need to be addressed through further research. However, the compound's unique chemical properties and its demonstrated biological activity make it a valuable tool for advancing our understanding of disease mechanisms and developing next-generation therapeutics.

In conclusion, 1-(Pyridin-2-yl)hexan-1-amine hydrochloride (CAS: 1864057-37-3) represents a compelling area of research in chemical biology and drug discovery. Its optimized synthesis, diverse pharmacological effects, and potential therapeutic applications highlight its significance in the field. Future studies should focus on overcoming the existing challenges and exploring its full potential in clinical settings.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)